In vitro fertilization impact on the risk of breast cancer
Abstract
Breast cancer, with its increasing incidence and high mortality rates, remains a major global health challenge, significantly impacting individuals, families, and societies. Understanding the multifactorial risk factors contributing to its development is crucial for effective prevention and management. Hormonal factors play a significant role in breast cancer development. Given that ovarian steroid hormones influence breast function, any gonadotropin hormone or fertility drug that stimulates ovulation may also impact breast tissue. Contrary to the findings of studies with smaller sample sizes, concerns have emerged regarding the potential increased risk of breast cancer following in vitro fertilization (IVF) treatments. This article explores the potential risk of breast cancer associated with hormonal cycles during IVF, supported by a literature review and a case study conducted in a tertiary hospital in Bucharest, Romania. The case involves a 38-year-old patient with a history of hormonally treated endometriosis and five IVF cycles, who presented for mammographic and ultrasound screening. The screening revealed multicentric and multifocal BIRADS-5 lesions, with histopathological and immunohistochemical analysis confirming invasive breast carcinoma of no special type with ductal carcinoma in situ, HER2 positive (3+), estrogen receptor and progesterone receptor negative, and a Ki-67 proliferation index of 50%.
##plugins.themes.bootstrap3.article.details##
breast cancer , mammography, screening, ivf, increased risk
2. Zubair M, Wang S, Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol. 2021 Feb 26;11:632079. doi: 10.3389/fphar.2020.632079. PMID: 33716731; PMCID: PMC7952319.
3. International Agency for Research on Cancer. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. [https://gco.iarc.fr/today available at 09/01/2024].
4. Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Sep 28;394(10204):1159-1168. doi: 10.1016/S0140-6736(19)31709-X. PMID: 31474332; PMCID: PMC6891893.
6. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43. doi: 10.1186/bcr1525. PMID: 16859501; PMCID: PMC1779465.
7. Klip H, Burger CW, de Kraker J, van Leeuwen FE; OMEGA-project group. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Hum Reprod. 2001 Nov;16(11):2451-8. doi: 10.1093/humrep/16.11.2451. PMID: 11679537.
8. Farhud D, Zokaei S, Keykhaei M, Zarif Yeganeh M. Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article. Iran J Public Health. 2019 Dec;48(12):2124-2132. PMID: 31993380; PMCID: PMC6974869.
9. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril. 2003 Apr;79(4):844-51. doi: 10.1016/s0015-0282(02)04950-6. PMID: 12749419.
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 Jan 19;354(3):270-82. doi: 10.1056/NEJMra050776. PMID: 16421368.
11. Joubert A, Van Zyl H, Laurens J, Lottering ML. C2- and C4-position 17beta-estradiol metabolites and their relation to breast cancer. Biocell. 2009 Dec;33(3):137-40. PMID: 20067028.
12. Farhud DD, Zokaei S, Keykhaei M, et al. In-Vitro Fertilization Impact on the Risk of Breast Cancer: A Review Article. Iran J Public Health. 2021 Mar;50(3):438-447. doi: 10.18502/ijph.v50i3.5583. PMID: 34178791; PMCID: PMC8214614.
13. Ortega I, García-Velasco JA, Pellicer A. Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes. J Assist Reprod Genet. 2018 Oct;35(10):1751-1762. doi: 10.1007/s10815-018-1258-6. PMID: 30056596; PMCID: PMC6150894.
14. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online. 2002 May-Jun;4(3):303-10. doi: 10.1016/s1472-6483(10)61821-4. PMID: 12709286.
15. Yilmaz S, Yilmaz Sezer N, Gönenç İM, İlhan SE, Yilmaz E. Safety of clomiphene citrate: a literature review. Cytotechnology. 2018 Apr;70(2):489-495. doi: 10.1007/s10616-017-0169-1. PMID: 29159661; PMCID: PMC5851961.
16. Petrangelo A, Czuzoj-Shulman N, Tulandi T, Azoulay L, Abenhaim HA. Ovulation Induction for Infertility the Risk of Breast Cancer: A Population-Based Case-Control Study [11B]. Obst Gynecol. 131:p 22S, 2018. doi: 10.1097/01.AOG.0000532913.25817.0e
17. Leão Rde B, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo). 2014;69(4):279-93. doi: 10.6061/clinics/2014(04)10. PMID: 24714837; PMCID: PMC3971356.
18. Prodromidou A, Anagnostou E, Mavrogianni D, et al. Past, Present, and Future of Gonadotropin Use in Controlled Ovarian Stimulation During Assisted Reproductive Techniques. Cureus. 2021 Jun 15;13(6):e15663. doi: 10.7759/cureus.15663. PMID: 34277255; PMCID: PMC8280946.
19. Schüler-Toprak S, Treeck O, Ortmann O. Human Chorionic Gonadotropin and Breast Cancer. Int J Mol Sci. 2017 Jul 21;18(7):1587. doi: 10.3390/ijms18071587. PMID: 28754015; PMCID: PMC5536074.
20. Cole L. Human chorionic gonadotropin (hCG). 2nd ed. Elsevier; 2014. p. 446.
21. Kölbl AC, Schlenk K, Behrendt N, Andergassen U. The importance of hCG in human endometrial adenocarcinoma and breast cancer. Int J Biol Markers. 2018 Jan;33(1):33-39. doi: 10.5301/ijbm.5000290. PMID: 28967068.
22. Kardana A, Taylor ME, Southall PJ, et al. Urinary gonadotrophin peptide--isolation and purification, and its immunohistochemical distribution in normal and neoplastic tissues. Br J Cancer. 1988 Sep;58(3):281-6. doi: 10.1038/bjc.1988.204. PMID: 3052560; PMCID: PMC2246594.
23. Kroener L, Dumesic D, Al-Safi Z. Use of fertility medications and cancer risk: a review and update. Curr Opin Obstet Gynecol. 2017 Aug;29(4):195-201. doi: 10.1097/GCO.0000000000000370. PMID: 28538003; PMCID: PMC5551049.
24. Brinton LA, Scoccia B, Moghissi KS, et al. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):584-93. doi: 10.1158/1055-9965.EPI-13-0996. PMID: 24700523; PMCID: PMC3979528.
25. Del Pup L, Peccatori FA, Levi-Setti PE, Codacci-Pisanelli G, Patrizio P. Risk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors. Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8042-8059. doi: 10.26355/eurrev_201811_16434. PMID: 30536354.
26. Farland LV, Lind KE, Thomson CA, et al. Infertility and risk of postmenopausal breast cancer in the women's health initiative. Breast Cancer Res Treat. 2024 Jun;205(3):497-506. doi: 10.1007/s10549-024-07257-2. PMID: 38459395; PMCID: PMC11186618.
27. Cullinane C, Gillan H, Geraghty J, Evoy D, Rothwell J, McCartan D, McDermott EW, Prichard RS. Fertility treatment and breast-cancer incidence: meta-analysis. BJS Open. 2022 Jan 6;6(1):zrab149. doi: 10.1093/bjsopen/zrab149. PMID: 35143625; PMCID: PMC8830753.
28. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1400-7. doi: 10.1158/1055-9965.EPI-07-0075. PMID: 17585058.
29. Brinton LA, Trabert B, Shalev V, et al. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril. 2013 Apr;99(5):1189-96. doi: 10.1016/j.fertnstert.2012.12.029. PMID: 23375197; PMCID: PMC4030547.
30. van den Belt-Dusebout AW, van Leeuwen FE, Burger CW. Breast Cancer Risk After Ovarian Stimulation for In Vitro Fertilization-Reply. JAMA. 2016 Oct 25;316(16):1713-1714. doi: 10.1001/jama.2016.15243. PMID: 27784092.
31. Guleria S, Kjær SK, Albieri V, Frederiksen K, Jensen A. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs. Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):1986-1992. doi: 10.1158/1055-9965.EPI-19-0652. PMID: 31533944.
32. Katz D, Paltiel O, Peretz T, et al. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case-control study. Breast J. 2008 Nov-Dec;14(6):517-22. doi: 10.1111/j.1524-4741.2008.00641.x. PMID: 19000041.
33. Pappo I, Lerner-Geva L, Halevy A, et al. The possible association between IVF and breast cancer incidence. Ann Surg Oncol. 2008 Apr;15(4):1048-55. doi: 10.1245/s10434-007-9800-2. PMID: 18214616.
34. Tsafrir A, Lerner-Geva L, Zaslavsky-Paltiel I, et al. Cancer in IVF patients treated at age 40 years and older: long term follow-up. Reprod Biomed Online. 2020 Mar;40(3):369-373. doi: 10.1016/j.rbmo.2019.11.015. PMID: 32008887.
35. Stewart LM, Holman CD, Hart R, et al. In vitro fertilization and breast cancer: is there cause for concern? Fertil Steril. 2012 Aug;98(2):334-40. doi: 10.1016/j.fertnstert.2012.04.019. PMID: 22633651.
36. Taheripanah R, Balash F, Anbiaee R, Mahmoodi M, Akbari Sene A. Breast Cancer and Ovulation Induction Treatments. Clin Breast Cancer. 2018 Oct;18(5):395-399. doi: 10.1016/j.clbc.2018.03.003. PMID: 29628340.
37. Sung JS, Stamler S, Brooks J, et al. Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results. Radiology. 2016 Sep;280(3):716-22. doi: 10.1148/radiol.2016151419. PMID: 27097237; PMCID: PMC5006733.
38. Wellings E, Vassiliades L, Abdalla R. Breast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective? Cureus. 2016 Dec 28;8(12):e945. doi: 10.7759/cureus.945. PMID: 28133583; PMCID: PMC5268380.
39. US Preventive Services Task Force. Final recommendation statement: breast cancer: screening. 2016. [https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening Available at 28/8/2024].
40. Sunderam S, Kissin DM, Crawford SB, et al. Assisted Reproductive Technology Surveillance - United States, 2015. MMWR Surveill Summ. 2018 Feb 16;67(3):1-28. doi: 10.15585/mmwr.ss6703a1. PMID: 29447147; PMCID: PMC5829941.
41. Stewart LM, Hart R. Long-term cancer risks in women after treatment with IVF: do we have any answers yet? Womens Health (Lond). 2015 Jan;11(1):7-10. doi: 10.2217/whe.14.58. PMID: 25581049.
42. Sergentanis TN, Diamantaras AA, Perlepe C, et al. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014 Jan-Feb;20(1):106-23. doi: 10.1093/humupd/dmt034. PMID: 23884897.
43. Lo Russo G, Spinelli GP, Tomao S, et al. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther. 2013 Feb;13(2):149-57. doi: 10.1586/era.12.181. PMID: 23406556.
44. Zreik TG, Mazloom A, Chen Y, et al B. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010 Nov;124(1):13-26. doi: 10.1007/s10549-010-1140-4. PMID: 20809361.
45. Reigstad MM, Larsen IK, Myklebust TÅ, et al. Risk of breast cancer following fertility treatment--a registry based cohort study of parous women in Norway. Int J Cancer. 2015 Mar 1;136(5):1140-8. doi: 10.1002/ijc.29069. PMID: 25042052; PMCID: PMC4268160.
46. Lundberg FE, Johansson AL, Rodriguez-Wallberg K, et al. Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study. Breast Cancer Res. 2016 Apr 13;18(1):36. doi: 10.1186/s13058-016-0693-5. PMID: 27072636; PMCID: PMC4830010.
47. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol. 2012 Mar;198(3):W292-5. doi: 10.2214/AJR.10.6049. PMID: 22358028.
48. Kim EY, Chang Y, Ahn J, et al. Mammographic breast density, its changes, and breast cancer risk in premenopausal and postmenopausal women. Cancer. 2020 Nov 1;126(21):4687-4696. doi: 10.1002/cncr.33138. PMID: 32767699.
49. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor - a review. Placenta. 2008 Oct;29 Suppl B:169-77. doi: 10.1016/j.placenta.2008.08.007. PMID: 18790330.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.